Phosphorylation and cleavage of tau in non-AD tauopathies

被引:53
作者
Guillozet-Bongaarts, Angela L.
Glajch, Kelly E.
Libson, Emilie G.
Cahill, Michael E.
Bigio, Eileen
Berry, Robert W.
Binder, Lester I.
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA
[2] Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA
[3] Northwestern Univ, Feinberg Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Chicago, IL 60611 USA
[4] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
caspase; astrocytes; cortico-basal ganglionic degeneration; progressive supranuclear palsy; Pick's disease;
D O I
10.1007/s00401-007-0209-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The tau protein, well known as the primary component of neurofibrillary tangles, also comprises the Pick bodies found in Pick's disease (PiD) and the glial lesions associated with progressive supranuclear palsy (PSP) and cortico-basal ganglionic degeneration (CBD). Many of the tau alterations that are characteristic of Alzheimer's disease have also been identified in PSP and CBD. In this report, we examine three non-AD tauopathies (PSP, CBD, and PiD) for the presence of two specific tau alterations, phosphorylation at Ser422 and truncation at Asp421. We find that truncation at Asp421 is an alteration that is unique to neuronal lesions, occurring in Pick bodies as well as in neurofibrillary tangles, but not in lesions associated with glia. Conversely, phosphorylation at Ser422 is not only present in all these lesions, but identifies additional glial and neuronal pathology in disease-susceptible cortical regions. These results suggest that the molecular alterations of tau that occur during the initial process of tangle formation in AD are similar in non-AD tauopathies, but the middle and later changes are not common to all diseases.
引用
收藏
页码:513 / 520
页数:8
相关论文
共 31 条
[1]   Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration [J].
Arai, T ;
Ikeda, K ;
Akiyama, H ;
Tsuchiya, K ;
Iritani, S ;
Ishiguro, K ;
Yagishita, S ;
Oda, T ;
Odawara, T ;
Iseki, E .
ACTA NEUROPATHOLOGICA, 2003, 105 (05) :489-498
[2]  
Armstrong RA, 1999, NEUROPATH APPL NEURO, V25, P266
[3]   Tau epitope display in progressive supranuclear palsy and corticobasal degeneration [J].
Berry, RW ;
Sweet, AP ;
Clark, FA ;
Lagalwar, S ;
Lapin, BR ;
Wang, T ;
Topgi, S ;
Guillozet-Bongaarts, AL ;
Cochran, EJ ;
Bigio, EH ;
Binder, LI .
JOURNAL OF NEUROCYTOLOGY, 2004, 33 (03) :287-295
[4]   STAGING OF ALZHEIMERS-DISEASE-RELATED NEUROFIBRILLARY CHANGES [J].
BRAAK, H ;
BRAAK, E .
NEUROBIOLOGY OF AGING, 1995, 16 (03) :271-278
[5]   AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease [J].
BueeScherrer, V ;
Condamines, O ;
MourtonGilles, C ;
Jakes, R ;
Goedert, M ;
Pau, B ;
Delacourte, A .
MOLECULAR BRAIN RESEARCH, 1996, 39 (1-2) :79-88
[6]   The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology [J].
Carmel, G ;
Mager, EM ;
Binder, LI ;
Kuret, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (51) :32789-32795
[7]   Neuropathology of Pick's disease [J].
Dickson, DW .
NEUROLOGY, 2001, 56 (11) :S16-S20
[8]  
FEANY MB, 1995, ACTA NEUROPATHOL, V90, P37
[9]  
Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100
[10]   Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease [J].
García-Sierra, F ;
Wischik, CM ;
Harrington, CR ;
Luna-Muñoz, J ;
Mena, R .
JOURNAL OF CHEMICAL NEUROANATOMY, 2001, 22 (1-2) :65-77